All In Biotech

Drug Trial Radar · NCT02465515

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 9,463 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,463

Actual

Start

Jul 1, 2015

Primary completion

Feb 20, 2018

Study completion Mar 14, 2018

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Duke Clinical Research Institute
First posted
Jun 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.

Conditions

  • Diabetes Mellitus

Interventions

  • Albiglutide 30 mgBiological

    Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

  • Albiglutide 50 mgBiological

    Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

  • Albiglutide matching placeboBiological

    Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time PeriodTime frame: Median of 1.65 person years for CV follow-up time period

Locations

607 sites in 28 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Goodyear, Arizona

  • GSK Investigational Site

    Tempe, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Searcy, Arkansas

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    Lancaster, California

  • GSK Investigational Site

    Lomita, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Moreno Valley, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Marino, California

  • GSK Investigational Site

    San Ramon, California

  • GSK Investigational Site

    Simi Valley, California

  • GSK Investigational Site

    Stanford, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Littleton, Colorado

  • GSK Investigational Site

    Littleton, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Belle Glade, Florida

  • GSK Investigational Site

    Bradenton, Florida

  • GSK Investigational Site

    Bradenton, Florida

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Coral Springs, Florida

  • GSK Investigational Site

    Fleming Island, Florida

  • GSK Investigational Site

    Inverness, Florida

  • GSK Investigational Site

    Jacksonville, Florida

Showing 40 of 607 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.